PMID- 36624318
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20240104
IS  - 1862-3514 (Electronic)
VI  - 18
IP  - 1
DP  - 2023 Jan 10
TI  - The clinical effectiveness of denosumab (Prolia(R)) in patients with 
      hormone-sensitive cancer receiving endocrine therapy, compared to 
      bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a 
      systematic review and network meta-analysis.
PG  - 18
LID - 10.1007/s11657-023-01211-3 [doi]
AB  - This systematic review (SR) assessed the use of denosumab (Prolia(R)) to treat 
      osteoporosis in cancer patients receiving endocrine therapy. Denosumab was found 
      to prevent vertebral fractures and improve bone mineral density in cancer 
      patients with osteoporosis. This is the first SR to assess treating osteoporotic 
      cancer patients with denosumab. PURPOSE: This study assessed the effectiveness 
      and safety of denosumab (Prolia(R)) compared to bisphosphonates (alendronate, 
      ibandronate, risedronate, zoledronate), selective estrogen receptor modulators 
      (SERMs) (bazedoxifene, raloxifene) and placebo for the treatment of osteoporosis 
      in hormone-sensitive cancer patients receiving endocrine therapy (men with 
      prostate cancer [MPC] on hormone ablation therapy [HAT], and women with breast 
      cancer [WBC] on adjuvant aromatase inhibitor therapy [AAIT]). METHODS: Systematic 
      literature searches were conducted in three biomedical databases to identify 
      randomized controlled trials (RCTs). Frequentist network meta-analyses and/or 
      pairwise meta-analyses were performed on predetermined outcomes (i.e., 
      vertebral/nonvertebral fractures, bone mineral density [BMD], mortality, 
      treatment-related adverse events [AEs], serious AEs [SAEs], withdrawal due to 
      treatment-related AEs). RESULTS: A total of 14 RCTs (15 publications) were 
      included. Denosumab was found to prevent vertebral fractures in cancer patients 
      receiving endocrine therapy, relative to placebo. Similarly, denosumab, 
      zoledronate, and alendronate improved BMD at the femoral neck (FN) and lumbar 
      spine (LS) in MPC on HAT, relative to placebo. Denosumab, ibandronate and 
      risedronate improved BMD at the LS and total hip (TH) in WBC on AAIT, relative to 
      placebo. Denosumab and risedronate improved trochanteric (TRO) BMD in WBC on 
      AAIT, relative to placebo. Similarly, denosumab improved FN BMD in WBC on AAIT. 
      CONCLUSION: In MPC on HAT, denosumab (relative to placebo) was effective at 
      preventing vertebral fractures and improving BMD at the FN and LS. Moreover, in 
      WBC on AAIT, denosumab (relative to placebo) improved BMD at the FN, LS, TH, and 
      TRO, as well as prevent vertebral fracture.
CI  - (c) 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis 
      Foundation.
FAU - Nicolopoulos, Konstance
AU  - Nicolopoulos K
AD  - Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of 
      Surgeons, Adelaide, Australia.
FAU - Moshi, Magdalena Ruth
AU  - Moshi MR
AD  - Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of 
      Surgeons, Adelaide, Australia. college.asernip@surgeons.org.
FAU - Stringer, Danielle
AU  - Stringer D
AD  - Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of 
      Surgeons, Adelaide, Australia.
FAU - Ma, Ning
AU  - Ma N
AD  - Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of 
      Surgeons, Adelaide, Australia.
FAU - Jenal, Mathias
AU  - Jenal M
AD  - Health Technology Assessment Section, Health Insurance Benefits Division, Health 
      and Accident Insurance Directorate, Federal Office of Public Health (FOPH), Bern, 
      Switzerland.
FAU - Vreugdenburg, Thomas
AU  - Vreugdenburg T
AD  - Research & Evaluation incorporating ASERNIP-S, Royal Australasian College of 
      Surgeons, Adelaide, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20230110
PL  - England
TA  - Arch Osteoporos
JT  - Archives of osteoporosis
JID - 101318988
RN  - X1J18R4W8P (Alendronate)
RN  - 0 (Bone Density Conservation Agents)
RN  - 4EQZ6YO2HI (Denosumab)
RN  - 0 (Diphosphonates)
RN  - 0 (Hormones)
RN  - UMD7G2653W (Ibandronic Acid)
RN  - KM2Z91756Z (Risedronic Acid)
RN  - 0 (Selective Estrogen Receptor Modulators)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Alendronate/adverse effects
MH  - Bone Density/drug effects
MH  - *Bone Density Conservation Agents/adverse effects
MH  - *Denosumab/adverse effects
MH  - Diphosphonates/adverse effects
MH  - Hormones
MH  - Ibandronic Acid/adverse effects
MH  - *Neoplasms/drug therapy
MH  - Network Meta-Analysis
MH  - Osteoporosis/drug therapy
MH  - Risedronic Acid/adverse effects
MH  - Selective Estrogen Receptor Modulators/adverse effects
MH  - Spinal Fractures/prevention & control
MH  - Treatment Outcome
MH  - Zoledronic Acid/adverse effects
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Breast cancer
OT  - Denosumab
OT  - Endocrine therapy
OT  - Network meta-analysis
OT  - Prostate cancer
OT  - Systematic review
EDAT- 2023/01/10 06:00
MHDA- 2023/01/12 06:00
CRDT- 2023/01/09 23:26
PHST- 2022/09/26 00:00 [received]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/01/09 23:26 [entrez]
PHST- 2023/01/10 06:00 [pubmed]
PHST- 2023/01/12 06:00 [medline]
AID - 10.1007/s11657-023-01211-3 [pii]
AID - 10.1007/s11657-023-01211-3 [doi]
PST - epublish
SO  - Arch Osteoporos. 2023 Jan 10;18(1):18. doi: 10.1007/s11657-023-01211-3.